MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma

Boonla, Chanchai; Sripa, Banchob; Thuwajit, Peti; Cha’on, Ubon; Puapairoj, Anucha; Misawa, Miwa; Wongkham, Sopit

doi:10.3748/wjg.v11.i32.4939

Cited by 50 publications

(39 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overexpression of MUC5AC in PDA has been reported in 70% to 100% of the cases in several studies [13,14,25]. Similarly, a high frequency of MUC5AC expression has been reported in cholangiocarcinoma [11,13,14,[26][27][28][29] and gallbladder adenocarcinoma [11,15]. In the studies where ICC and extrahepatic cholangiocarcinoma (ECC) were separately evaluated, it was apparent that ECCs more frequently expressed MUC5AC than ICCs.…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma

et al. 2014

View full text Add to dashboard Cite

Summary Distinction between primary intrahepatic cholangiocarcinoma (ICC) and metastatic pancreatic ductal adenocarcinoma (PDA) on a liver biopsy is essentially impossible histologically but has important clinical implications. In this study, 41 ICCs and 60 PDAs were immunohistochemically evaluated for the expression of S100P, pVHL, IMP3, maspin, MUC5AC, and CK17 proteins. The results showed pVHL expression in 29 (71%) ICCs but in only 3 (5%) PDAs. S100P, MUC5AC, and CK17 were frequently expressed in PDAs, seen in 57 (95%), 40 (67%), and 36 (60%) cases, respectively. In contrast, only 11 (27%), 5 (12%), and 5 (12%) ICC cases expressed these proteins. IMP3 was expressed in 37 (90%) ICC and 54 (90%) PDA cases with equal frequency. All 60 (100%) PDA and 30 (73%) ICC cases showed positive maspin immunoreactivity. A S100P−/pVHL+/MUC5A C−/CK17− staining pattern was essentially indicative of ICC, whereas the S100P+/pVHL−/MUC5AC+/ CK17+ and S100P+/pVHL−/MUC5AC−/CK17+ staining patterns were suggestive of PDA. These observations demonstrate that S100P, pVHL, MUC5AC, and CK17 are a useful immunohistochemical panel that may help distinguish primary ICC from metastatic PDA.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Consistent with this finding, another study showed that MUC1 expression was not associated with histological subtypes in OV-associated Thai ICCs. 42 We also identified genes expressed differentially between MF-type and periductal infiltrating-type ICCs. Notably, IQGAP1 was in the list of genes relatively enhanced in periductal infiltrating-type ICCs compared with MF-type ICCs.…”

Section: Discussionmentioning

confidence: 99%

Comparison of gene expression profiles between Opisthorchis viverrini and non‐Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma†

et al. 2006

View full text Add to dashboard Cite

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary cancer in the liver, and its incidence is highest in the northeastern part of Thailand. ICCs in this region are known to be associated with infection with liver flukes, particularly Opisthorchis viverrini (OV), as well as nitrosamines from food. To clarify molecular mechanisms of ICC associated with or without liver flukes, we analyzed gene expression profiles of OV-associated ICCs from 20 Thai patients and compared their profiles with those of 20 Japanese ICCs that were not associated with OV, by means of laser microbeam microdissection and a cDNA microarray containing 27,648 genes. We identified 77 commonly upregulated genes and 325 commonly downregulated genes in the two ICC groups. Unsupervised hierarchical cluster analysis separated the 40 ICCs into two major branches almost completely according to the fluke status. The putative signature of OV-associated ICC exhibited elevated expression of genes involved in xenobiotic metabolism (UGT2B11, UGT1A10, CHST4, SULT1C1), whereas that of non-OV-associated ICC represented enhanced expression of genes related to growth factor signaling (TGFBI, PGF, IGFBP1, IGFBP3). Additional random permutation tests identified a total of 49 genes whose expression levels were significantly different between the two groups. We also identified genes associated with macroscopic type of ICCs. In conclusion, these data may not only contribute to clarification of common and OV-specific mechanisms underlying ICC, but also may serve as a starting point for the identification of novel diagnostic markers or therapeutic targets for the disease.

show abstract

“…Of the nine studies that have examined the prognostic value of MUC1 in CC, all except one have demonstrated a significant correlation between MUC1 expression and decreased survival, both on univariate and multivariate survival analyses (61,62,(101)(102)(103)(104)(105)(106)(107).…”

Section: Muc1mentioning

confidence: 99%

Prognostic molecular markers in cholangiocarcinoma: A systematic review

Briggs

Neal

Mann

et al. 2009

European Journal of Cancer

View full text Add to dashboard Cite

The worldwide incidence of cholangiocarcinoma (CC) is steadily rising, the United Kingdom incidence now exceeding 1000 cases per year. It is an aggresive malignancy typified by unresponsiveness to existing chemotherapy and radiotherapy regimes in the vast majority of cases. Surgery offers the only hope of a cure, though postoperative disease recurrence is common, with 5-year survival rates following resection of less then 25%. Developments in molecular techniques and improved understanding of the basis of carcinogenesis in CC has led to examination of the role of biomarkers in predicting poor outcome. This systematic review examines published evidence relating to the prognostic significance of these molecular markers in CC. Of the molecular markers which have been investigated to date p53 mutation, cyclins, proliferation indices, mucins, CA19-9, CRP, and aneuploidy appear to hold significant potential as predictors of outcome in CC. These and other biomarkers may themselves represent novel therapeutic targets for CC.

show abstract

MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma

Cited by 50 publications

References 50 publications

Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma

Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma

Comparison of gene expression profiles between Opisthorchis viverrini and non‐Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma†

Prognostic molecular markers in cholangiocarcinoma: A systematic review

Contact Info

Product

Resources

About